

Datasheet: MCA477SBV710

## **BATCH NUMBER 100005482**

Description:	MOUSE ANTI HUMAN HLA DP DQ DR:StarBright Violet 710		
Specificity:	HLA DP DQ DR		
Format:	StarBright Violet 710		
Product Type:	Monoclonal Antibody		
Clone:	WR18		
Isotype:	lgG2a		
Quantity:	100 TESTS/0.5ml		

# **Product Details**

## **Applications**

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit <a href="www.bio-rad-antibodies.com/protocols">www.bio-rad-antibodies.com/protocols</a>.

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry				Neat

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Target Species	Human		
Product Form	Purified IgG conjugate	ed to StarBright Violet	710 - liquid
Max Ex/Em	Fluorophore	Excitation Max (nm)	Emission Max (nm
	StarBright Violet 710	401	713
Preparation	Purified IgG prepared supernatant	by affinity chromatog	raphy on Protein G
Buffer Solution	Phosphate buffered sa	aline	
Preservative	0.09% Sodium Azide	(NaN <sub>3</sub> )	
Stabilisers	1% Bovine Serum Alb	oumin	
	0.1% Pluronic F68		
	0.1% PEG 3350		

ı	m	m	u	n	o	a	e	n
•	•••	•••	•	••	•	3	•	

Human HLA Class II (DP, DQ, DR).

#### **Fusion Partners**

Spleen cells from immunized BALB/c mice were fused with cells from NS0 mouse myeloma cell line.

### Specificity

Mouse anti Human HLA DP DQ DR antibody, clone WR18 reacts with a monomorphic determinant common to DP, DQ and DR beta chains, which are expressed by antigen presenting cells, B cells, monocytes and activated T lymphocytes.

The major histocompatibility complex (MHC) is a cluster of genes that are important in the immune response to infections. In humans, this complex is referred to as the human leukocyte antigen (HLA) region. There are 3 major MHC class II proteins encoded by the HLA which are HLA DP, HLA DQ and HLA DR.

### Flow Cytometry

Use 5ul of the suggested working dilution to label 10<sup>6</sup> cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.

#### References

- 1. Moore, K. *et al.* (1987) Use of the monoclonal antibody WR17, identifying the CD37 gp40-45 Kd antigen complex, in the diagnosis of B-lymphoid malignancy. <u>J Pathol</u> 152:13-21.
- 2. Kissner, T.L. *et al.* (2011) Activation of MyD88 Signaling upon Staphylococcal Enterotoxin Binding to MHC Class II Molecules. PLoS One. 6: e15985.
- 3. Chia, J.S. *et al.* (2001) Human T-cell responses to the glucosyltransferases of *Streptococcus mutans*. Clin Diagn Lab Immunol. 8: 441-5.
- 4. Chang, Y.C. *et al.* (2008) Epigenetic control of MHC class II expression in tumorassociated macrophages by decoy receptor 3. <u>Blood. 111: 5054-63.</u>
- 5. Litzinger, M.T. *et al.* (2009) Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients. <u>Cancer Immunol Immunother</u>. 58: 955-65.
- 6. Sadallah, S. *et al.* (2011) Microparticles (ectosomes) shed by stored human platelets downregulate macrophages and modify the development of dendritic cells. <u>J Immunol.</u> 186: 6543-52.
- 7. Sabbah, S. *et al.* (2012) T-cell immunity to Kaposi sarcoma-associated herpesvirus: recognition of primary effusion lymphoma by LANA-specific CD4+ T cells. <u>Blood. 119 (9): 2083-92.</u>
- 8. John, J. *et al.* (2010) Differential effects of Paclitaxel on dendritic cell function. <u>BMC</u> Immunol. 11:14.
- 9. Palmer, K.J. *et al.* (2000) Interferon-alpha (IFN-alpha) stimulates anti-melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC). Clin Exp Immunol. 119: 412-8.
- 10. Silk, K.M. *et al.* (2012) Rapamycin conditioning of dendritic cells differentiated from human ES cells promotes a tolerogenic phenotype. <u>J Biomed Biotechnol. 2012: 172420.</u>
- 11. Elias, F. *et al.* (2003) Strong cytosine-guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs. <u>J. Immunol.</u> 171: 3697-704.
- 12. Silk, K.M. *et al.* (2012) Cross-presentation of tumour antigens by human induced pluripotent stem cell-derived CD141(+)XCR1+ dendritic cells. <u>Gene Ther. 19 (10):</u> 1035-40.

- 13. Adamski, J. (2004) 17{beta}-Estradiol Inhibits Class II MHC Expression: Influence on Histone Modifications and CBP Recruitment to the Class II MHC Promoter Molecular Endocrinology 18:1963
- 14. Keating, S. *et al.* (2002) The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules. J Virol. 76: 8179-88.
- 15. Trefzer, U. *et al.* (2000) Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma. <u>Int J Cancer. 85 (5): 618-26.</u>
- 16. Hayman, M.W. *et al.* (2006) Soluble human leukocyte antigen: a diagnostic indicator of rheumatoid arthritis? J Immunol Methods. 315 (1-2): 19-26.
- 17. Manna, D. *et al.* (2012) WR18 MONOCLONAL ANTIBODY: A SINGLE ANTIBODY TO DETECT HLA DR, DP AND DQ ANTIGENS. <u>Abstracts/Human immunology 73:49-167</u> abstract 36P
- 18. Neumann, F. *et al.* (2004) Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes. <u>Cancer Immunol Immunother</u>. 53 (7): 589-99.
- 19. Neumann F *et al.* (2004) Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2. Int J Cancer. 112 (4): 661-8.
- 20. Iking-Konert C *et al.* (2005) Transdifferentiation of polymorphonuclear neutrophils to dendritic-like cells at the site of inflammation in rheumatoid arthritis: evidence for activation by T cells. <u>Ann Rheum Dis. 64 (10): 1436-42.</u>
- 21. Hönger, G. *et al.* (2015) Inter-individual differences in HLA expression can impact the CDC crossmatch. <u>Tissue Antigens</u>. 85 (4): 260-6.
- 22. del Pilar Martin, M. *et al.* (2008) Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. <u>Arch Neurol. 65 (12):</u> 1596-603.
- 23. Noble, P. *et al.* (2013) High levels of cleaved caspase-3 in colorectal tumour stroma predict good survival. Br J Cancer. 108 (10): 2097-105.
- 24. Llewelyn, M. *et al.* (2004) HLA class II polymorphisms determine responses to bacterial superantigens. <u>J Immunol. 172 (3): 1719-26.</u>
- 25. Koschwanez, H. *et al.* (2015) Stress-related changes to immune cells in the skin prior to wounding may impair subsequent healing. <u>Brain Behav Immun. 50: 47-51.</u>
- 26. Ziegler, C.G.K. *et al.* (2019) Constitutive Activation of the B Cell Receptor Underlies Dysfunctional Signaling in Chronic Lymphocytic Leukemia. <u>Cell Rep. 28 (4): 923-937.e3.</u>

Storage	Store at +4°C. DO NOT FREEZE. This product should be stored undiluted.
Guarantee	12 months from date of despatch
Acknowledgements	This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
Health And Safety Information	Material Safety Datasheet documentation #20471 available at: <a href="https://www.bio-rad-antibodies.com/SDS/MCA477SBV710">https://www.bio-rad-antibodies.com/SDS/MCA477SBV710</a> 20471

# **Related Products**

# **Recommended Useful Reagents**

<u>HUMAN SEROBLOCK (BUF070A)</u> <u>HUMAN SEROBLOCK (BUF070B)</u>

 North & South
 Tel: +1 800 265 7376
 Worldwide
 Tel: +44 (0)1865 852 700
 Europe
 Tel: +49 (0) 89 8090 95 21

 America
 Fax: +1 919 878 3751
 Fax: +44 (0)1865 852 739
 Fax: +49 (0) 89 8090 95 50

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets 'M380269:210507'

## Printed on 11 Apr 2025

© 2025 Bio-Rad Laboratories Inc | Legal | Imprint